Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

ilure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Three Months Ended Year Ended

December 31, December 31, December 31, December 31,

2007 2006 2007 2006

Revenues from

services $ - $ - $ - $ -

Operating expenses:

Research and

development 12,574,735 7,939,988 47,234,867 52,070,776

General and

administrative 9,472,938 4,467,225 32,803,508 13,637,664

Total

operating

expenses 22,047,673 12,407,213 80,038,375 65,708,440

Loss from

operations (22,047,673) (12,407,213) (80,038,375) (65,708,440)

Interest income 1,299,076 516,291 5,907,219 2,202,654

Interest expense - (4) - (4,833)

Other income - - 71,345 -

'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter ... — a revolutionary new archwire that allows orthodontists to simultaneously apply different forces ... the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to ...
(Date:6/29/2015)... ... 2015 , ... The global microfluidics market is expected to ... to 2020). The market is mainly driven by the rising geriatric population, growing ... lack of adequate healthcare and research infrastructure in emerging markets, dearth of skilled ...
(Date:6/29/2015)... According to a new market research report "Aptamers Market ... by Technology (SELEX, Other Technologies), by End Users (Academic Research ... 2020", published by MarketsandMarkets, the global Aptamers Market is expected ... 2015, at a CAGR of 17.89%. Browse ... igures spread through 125 P ages ...
(Date:6/26/2015)... MILFORD, Mass. , June 26, 2015 /PRNewswire/ ... in vitro diagnostics manufacturers, today announced that it ... (CRADA) with the National Cancer Institute (NCI), part ... reference materials and positive controls for cancer assays. ... to mix and accurately quantitate control DNA biosynthetics ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... diagnostics for animals and humans, today,announced that it ... a private placement with a group of existing ... AspenBio will receive,approximately $18 million in gross proceeds ...
... N.J., Dec. 20 Memory,Pharmaceuticals Corp. (Nasdaq: ... in a randomized, double-blind, placebo-controlled Phase 2a clinical,trial ... receptor partial,agonist, in cognitive impairment associated with schizophrenia ... tolerability and cognitive effects,of three doses of MEM ...
... /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: CHBT), a ... marketing and,distribution of probiotics dietary supplements, today announced ... Eastern Time on Monday, August 13,2007, to discuss ... June 30, of its 2008 fiscal year. ...
Cached Biology Technology:AspenBio Pharma Announces $18 Million Private Placement of Common Stock 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results 2
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... in the brains of rats to help focus ... sensory pathways to make it easier to block ... found. , Their report in the Journal of ... with attention deficit and hyperactivity disorders to improve ...
... unique nanoparticles that convert laser light into useful information, ... pH meter. , The discovery, which appears online this ... the first potential means of measuring accurate pH changes ... tissue and cells. , "Almost every biologist I speak ...
... PLoS Genetics has published the findings of a team ... Institute that provides a whole genome analysis of the ... as Dictyostelium. , Led by Dr. Janet ... of kinases, which are enzymes involved in cell communication ...
Cached Biology News:Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3Rice scientists make first nanoscale pH meter 2Scientists elucidate the kinome of key model organism 2